ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0462

Lupus-like Autoimmunity and Increased Interferon Response in Patients with STAT3-deficient Hyper-IgE Syndrome

Brian Dizon1, Rishi Goel2, Shuichiro Nakabo2, Amanda Urban2, Meryl Waldman2, Lilian Howard2, Dirk Darnell2, Munir Buhaya2, Sarfaraz Hasni3, Mariana Kaplan4, Alexandra Freeman2 and Sarthak Gupta1, 1National Institutes of Health, BETHESDA, MD, 2National Institutes of Health, Bethesda, 3Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD

Meeting: ACR Convergence 2020

Keywords: immunology, innate immunity, interferon, neutrophils, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases I: Mechanisms of Disease (0459–0463)

Session Type: Abstract Session

Session Time: 10:00AM-10:50AM

Background/Purpose: Autosomal dominant hyper-IgE syndrome (AD-HIES), also known as Job’s syndrome, is a rare primary immunodeficiency caused by dominant-negative loss-of-function (LOF) mutations in signal transducer and activator of transcription 3 (STAT3). STAT3 LOF patients develop dermatitis, recurrent infections, and elevated serum IgE. Autoimmunity and auto-inflammation are common complication of primary immune deficiencies; however, systemic autoimmune features and the role of innate immune system are not well-characterized in AD-HIES.

Methods: A retrospective chart review of patients with STAT3 LOF seen at the National Institutes of Health was performed to identify patients who also had clinical and serologic features of systemic lupus erythematosus (SLE), as defined by American College of Rheumatology (ACR) 1997 classification criteria. To characterize lupus-associated innate immune dysregulation, type I interferon (IFN) stimulated genes (ISGs) were quantified by RT-PCR in neutrophils,  in vitro neutrophil extracellular trap (NET) formation was measured by immunofluorescence, and serum anti-NET IgG autoantibodies were quantified by ELISA.

Results: We identified 10 out of 158 individuals (prevalence ~6.3%) with genetically confirmed STAT3 LOF mutations who developed systemic lupus erythematosus (SLE) or SLE-like manifestations, including immune complex glomerulonephritis (40%), cytopenias (50%), cutaneous disease (40%), and arthritis (40%). STAT3 LOF patients with SLE features were predominantly female (70%), and the onset of lupus and lupus-like disease features occurred between 12-24 years of age. All patients had positive ANA (100%), with a majority having anti-double-stranded DNA antibodies (90%), and hypocomplementemia (70%). Other lupus-associated-autoantibodies were also detected (Table 1). Immunosuppressive medications were required in 8 patients with systemic autoimmune features, which were well-tolerated and led to improvement in clinical symptoms. STAT3 LOF subjects with and without clinical features of SLE had increased expression of ISGs in neutrophils when compared to healthy controls. Increased spontaneous NET formation and anti-NET autoantibodies were observed in LOF STAT3 subjects, independent of the presence or absence of lupus-like symptoms and at higher levels than healthy controls (Figure 1).

Conclusion: Although autoimmunity is not a common finding in STAT3 LOF patients, we have identified SLE or SLE-like disease in about 6% of our cohort, with a high incidence of kidney involvement.  These findings are associated with immune dysregulation characteristic of SLE including an increased IFN signature, NET formation, and  various autoantibodies, including anti-NET antibodies. Significant immune dysregulation associated with dominant-negative STAT3 LOF mutations may explain the increased prevalence of systemic autoimmunity in these patients. Given this association, we recommend that patients with STAT3 LOF mutations be considered for rheumatology consultation for early recognition and treatment of SLE. The increased IFN signature also raises the potential for JAK-STAT modulation for therapy in these patients.

Table 1. Clinical characteristics of STAT3 LOF patients with lupus and lupus-like autoimmunity. Patients (n=10) with STAT3 LOF mutations were identified to have clinical and serologic features of lupus. Demographic information, disease manifestations, clinical laboratory data, and historic treatment protocols are shown. Diagnosis of lupus and lupus-like disease was made on the basis of fulfilling ACR 1997 classification criteria. Updated classification criteria for systemic lupus, SLICC 2012 and ACR 2017, are shown for comparison. Abbreviations are the following: W= white, AA= African-American, L= Latino, PI= Pacific Islander, ESRD= end-stage renal disease, ITP= idiopathic thrombocytopenic purpura, AIHA= autoimmune hemolytic anemia, IVIG= intravenous immunoglobulin, IVIG= intravenous immunoglobulin. 1Age at onset of lupus symptoms. 2Delineation of lupus and non-lupus symptoms is unclear at this time.

Figure 1. Increased interferon response, neutrophil extracellular trap (NET) formation, and anti-NET antibodies in patients with AD-HIES. (A) RT-PCR for interferon-stimulated gene expression in neutrophils from healthy controls (n=6), STAT3 LOF (n=7), and STAT3 LOF + SLE (n=4) patients. (B) Anti-NET IgG antibodies were measured in serum by ELISA in healthy controls (n=8), STAT3 LOF (n=8), STAT3 LOF + SLE (n=5), and SLE (n=10) patients. (C) Immunofluorescence for spontaneous NET formation in healthy controls (n=8), STAT3 LOF (n=7), and STAT3 LOF + SLE (n=5) patients; MPO (red), DNA (Hoechst, blue). (D) NETs were further quantified as percentage of neutrophils forming extracellular traps. Statistics were calculated by non-parametric Kruskal-Wallis test with Dunn’s correction (A,B,C) or non-parametric Mann-Whitney test (D). *p>0.05, **p>0.01, ns=not significant.


Disclosure: B. Dizon, None; R. Goel, None; S. Nakabo, None; A. Urban, None; M. Waldman, None; L. Howard, None; D. Darnell, None; M. Buhaya, None; S. Hasni, None; M. Kaplan, None; A. Freeman, None; S. Gupta, None.

To cite this abstract in AMA style:

Dizon B, Goel R, Nakabo S, Urban A, Waldman M, Howard L, Darnell D, Buhaya M, Hasni S, Kaplan M, Freeman A, Gupta S. Lupus-like Autoimmunity and Increased Interferon Response in Patients with STAT3-deficient Hyper-IgE Syndrome [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/lupus-like-autoimmunity-and-increased-interferon-response-in-patients-with-stat3-deficient-hyper-ige-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-like-autoimmunity-and-increased-interferon-response-in-patients-with-stat3-deficient-hyper-ige-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology